Prenatal therapy is an exciting emerging field for rare genetic diseases. XLHED is one of only a small number of rare diseases in the world with a prenatal therapeutic clinical trial currently enrolling.
Edelife is a phase 2, open label, international multicenter clinical trial of prenatal investigational treatment ER004. Edelife eligibility is specific to pregnant woman carriers of XLHED expecting a boy with XLHED. However, pregnant woman with confirmed or suspected hereditary ectodermal dysplasia (HED) unsure of their XLHED status may also be eligible for screening. Early patient referral is essential.
This is a website about the Edelife Clinical Trial dedicated to Healthcare Professionals.
This information is presented only for providing overview information about a clinical trial with an investigational product. It should not be construed as a recommendation for an unapproved use.
I certify that I am a Healthcare Professional and I have read the information above:
This is a website about the Edelife Clinical Trial dedicated to Healthcare Professionals.